- Home
- QTRX vs TVRD Comparison
QTRX vs TVRD Comparison
Compare QTRX & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTRX
- TVRD
- Stock Information
- Founded
- QTRX 2007
- TVRD 2017
- Country
- QTRX United States
- TVRD United States
- Employees
- QTRX N/A
- TVRD N/A
- Industry
- QTRX Biotechnology: Laboratory Analytical Instruments
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- QTRX Industrials
- TVRD Health Care
- Exchange
- QTRX Nasdaq
- TVRD Nasdaq
- Market Cap
- QTRX 241.2M
- TVRD 246.5M
- IPO Year
- QTRX 2017
- TVRD N/A
- Fundamental
- Price
- QTRX $5.02
- TVRD $3.95
- Analyst Decision
- QTRX Hold
- TVRD Buy
- Analyst Count
- QTRX 4
- TVRD 7
- Target Price
- QTRX $11.75
- TVRD $51.67
- AVG Volume (30 Days)
- QTRX 501.4K
- TVRD 732.1K
- Earning Date
- QTRX 11-10-2025
- TVRD 11-21-2025
- Dividend Yield
- QTRX N/A
- TVRD N/A
- EPS Growth
- QTRX N/A
- TVRD N/A
- EPS
- QTRX N/A
- TVRD N/A
- Revenue
- QTRX $125,784,000.00
- TVRD N/A
- Revenue This Year
- QTRX N/A
- TVRD N/A
- Revenue Next Year
- QTRX $37.03
- TVRD N/A
- P/E Ratio
- QTRX N/A
- TVRD N/A
- Revenue Growth
- QTRX N/A
- TVRD N/A
- 52 Week Low
- QTRX $4.05
- TVRD $3.94
- 52 Week High
- QTRX $15.67
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- QTRX 39.12
- TVRD 18.95
- Support Level
- QTRX $4.93
- TVRD $4.63
- Resistance Level
- QTRX $5.46
- TVRD $5.00
- Average True Range (ATR)
- QTRX 0.30
- TVRD 0.38
- MACD
- QTRX -0.09
- TVRD 0.54
- Stochastic Oscillator
- QTRX 7.17
- TVRD 0.00
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.